Live biotherapeutic/Microbiome Based Therapeutics Market Size is valued at USD 73.25 Bn in 2024 and is predicted to reach USD 142.81 Bn by the year 2034 at a 7.04% CAGR during the forecast period for 2025-2034.
A live microbe is utilized in a Live Biotherapeutic product to treat, prevent, or cure a disease. Microorganisms that may be beneficial to health have been discovered as the human microbiome, and its relationship to human health has come to be better understood. These microorganisms have a lot of potential for use as Live Biotherapeutic products in clinical settings. Several clinical trials are being conducted to assess their potential as a treatment. LBPs are believed to have biological effects by modulating the host-microbiota rather than directly acting on known targets or distant organs, tissues, or receptors. Importantly, LBPs will have a biological effect by influencing the local ecosystem, other microorganisms, and their interactions with the host.
Throughout the forecast period, market growth is anticipated to be driven by rising research and development efforts, as well as an expanding pipeline of microbiome-targeting therapies that are anticipated to treat a wide range of serious diseases. The development of new drugs and clinical trial activities for the treatment of diseases are being aided by ongoing innovation and technological advancements.
In 2019, 4D pharma collaborated with MSD to research and develop Live Biotherapeutics for vaccines. 4D's proprietary MicroRx® platform will be combined with MSD's expertise in developing and commercializing novel vaccines. During the forecast period, significant growth opportunities are anticipated as government funding and the R&D budget for drug development both increases. Over 640 patents focused on microbiome therapeutics were approved in 2020. The complexities occur due to a lack of expertise, specialized infrastructure, the need for astronomical capital expenditures, capacity limitations, and restrictions on ensuring compliance with good manufacturing practices (GMP).
The Live Biotherapeutic Product Market is segmented into By Product Which consists of VOWST (SER-109), REBYOTA, Visbiome, Other Pipeline Products. Whereas, By Target Disease Indication, the segmentation includes Recurrent C. Difficile Infection, Dietary Management of Microbial Imbalance, Other Indications. The segment Route Of Administration which includes Oral and Rectal Therapeutics. The Distribution Channel segment consists of Direct Sales, Pharmacies, Online Platforms. Whereas, By End User, the market is divided into Healthcare Facilities, Home Healthcare.
Regionally, North America is anticipated to experience brisk growth during the forecast period as a result of rising demand and the significant COVID-19 effect. Large sums of money are given to businesses to research Live Biotherapeutic ingredients and create new products.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 73.25 Bn |
| Revenue Forecast In 2034 | USD 142.81 Bn |
| Growth Rate CAGR | CAGR of 7.04% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, Target Disease Indication, Route Of Administration, Distribution channel, end user |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | 4D Pharma, Adiso Therapeutics, Alveolus Bio Inc, AOBiome Therapeutics Inc, Assembly Biosciences, Azitra, Biomica, Destiny Pharma, Destiny Pharma plc, EnteroBiotix Limited, Finch Therapeutics, Infant Bacterial Therapeutics AB, MaaT Pharma, Microbiotica, OSEL Inc, OxThera, Scioto Biosciences Inc, Second Genome, Seres Therapeutics, Servatus Limited, Siolta Therapeutics, Vedanta Biosciences, YSOPIA Bioscience. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Live biotherapeutic/Microbiome Based Therapeutics Market By Product
Live biotherapeutic/Microbiome Based Therapeutics Market By Route Of Administration
Live biotherapeutic/Microbiome Based Therapeutics Market By Target Disease Indication
Live biotherapeutic/Microbiome Based Therapeutics Market By Distribution Channel
Live biotherapeutic/Microbiome Based Therapeutics Market By End User
Live biotherapeutic/Microbiome Based Therapeutics Market By Region
North America Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
Europe Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
Asia Pacific Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
Latin America Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
Middle East & Africa Live biotherapeutic/Microbiome Based Therapeutics Market, by Country,
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.